Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2010

View Archived Issues

SYN-115 enhances effects of levodopa in Parkinson's disease patients

FDA approves labeling update for Tibotec's Prezista for HIV-1

IND to test androxal in men with type 2 diabetes and hypogonadism now effective

Gilead reports fourth quarter 2009 results

PROSPER data indicate no effect of pravastatin sodium on cognitive decline in the elderly

Antitumor activity of GMX-1777 plus radiotherapy seen in head and neck cancer models

Possible correlation between gender and genotype reported in pediatric onset of CD

AstraZeneca discloses novel Nav1.7 voltage-gated sodium channel blockers

Princeton University claims quorum-sensing signaling modulators for bacterial infections

Boehringer Ingelheim claims new chemokine CCR10 receptor antagonists

Labopharm receives FDA approval for Oleptro for major depressive disorder

Pharmasset describes new prodrugs of NS5B inhibitors

New antiepileptic agents described by University of North Carolina at Chapel Hill

FDA requests additional information for Protalix's taliglucerase alfa NDA

Onyx agrees with the FDA on a SPA for planned phase III carfilzomib trial

Vantia's VA-106483 enters phase IIb trial for nocturia

FDA approves Xiaflex for debilitating hand disease

Recordati receives European approval for silodosin for BPH

NeuroSearch presents topline results from phase III Huntexil study

Evotec and Vifor sign agreement to identify preclinical candidate in anemia

Spectrum and TopoTarget sign agreement for HDAC inhibitor belinostat

FDA accepts for formal review Javelin's NDA for NSAID Dyloject

EMEA issues scientific advice to Hybrigenics for clinical development of inecalcitol

Seattle and Millennium initiate phase I combination clinical trial of brentuximab

Oxytocin attenuates methamphetamine self-administration in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...